FilingReader Intelligence
Glencore receives US FDA warning letter for Indore facility
July 12, 2025 at 04:19 PM UTC•By FilingReader AI
Glencore Pharmaceuticals received a U.S. FDA warning letter for its Indore facility following a February 3-14 inspection. The company said it does not expect the letter to disrupt supplies or existing revenues, and noted no data integrity issues were reported.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:GLENMARK•Bombay Stock Exchange
News Alerts
Get instant email alerts when Glenmark Pharmaceuticals publishes news
Free account required • Unsubscribe anytime